Clinical trials: Topotecan, active
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemotherapy (irinotecan or topotecan) in treating patients with solid tumors that may have spread from where it first…
- Conditions
- Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT04514497
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 23 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Extensive-stage Small-cell Lung Cancer
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.
- Trial name
- NCT05874401
- Testing
- Trilaciclib, Topotecan
- Where
- Spain
- Volunteers
- 302 people
- Sponsor
- Pharmacosmos A/S
SCLC, Extensive Stage
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
Small-cell lung cancer (SCLC) has a high degree of malignancy and extremely poor prognosis, slow progress in the treatment of ES-SCLC, and a more ideal posterior therapy needs to be explored.
- Trial name
- NCT07141771
- Testing
- Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide
- Volunteers
- 100 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Neuroblastoma
Rapid Administration Pilot for Infusing Dinutuximab
Dinutuximab is an immunotherapy that has greatly improved outcomes for children with high-risk neuroblastoma and is now a standard part of treatment for both newly diagnosed and relapsed disease.
- Trial name
- RAPID (NCT05421897)
- Testing
- Dinutuximab with Chemotherapy
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital Los Angeles
Retinoblastoma, Chemotherapy Effect
Topotecan and Melphalan for Retinoblastoma
The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.
- Trial name
- NCT04799002
- Testing
- Topotecan, Melphalan
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs
This phase II trial studies how well berzosertib (M6620) works when given in combination with topotecan hydrochloride (topotecan) compared with topotecan alone in treating patients with small cell lung cancer that has come back…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma
- Trial name
- NCT03896503
- Testing
- Berzosertib, Biopsy Procedure, Biospecimen Collection
- Where
- 33 sites in United States
- Volunteers
- 104 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of SHR-A1921 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian…
- Trial name
- NCT06394492
- Testing
- SHR-A1921, Doxorubicin, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 440 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Ovarian Cancer
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for…
- Trial name
- ASPENOVA (NCT07546500)
- Testing
- Investigator's choice of Chemotherapy, Azenosertib
- Where
- 59 sites in United States, Australia and 10 more
- Volunteers
- 420 people
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Brain and Central Nervous System Tumors
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
RATIONALE: In this study a combination of anti-cancer drugs (chemotherapy) is used to treat brain tumors in young children. Using chemotherapy gives the brain more time to develop before radiation is given.
- Trial name
- NCT00602667
- Testing
- Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy
- Where
- 6 sites in United States, Australia
- Volunteers
- 293 people
- Sponsor
- St. Jude Children's Research Hospital
Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy
Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment
Intravitreal topotecan exhibits strong anti-inflammatory, anti-proliferative, and anti-fibrotic properties, making it a promising option for preventing and treating proliferative vitreoretinopathy in rhegmatogenous retinal…
- Trial name
- TOPO-PT (NCT06818721)
- Testing
- Intravitreal topotecan, Retinal detachment surgery
- Where
- 2 sites in Canada
- Volunteers
- 394 people
- Sponsor
- Unity Health Toronto
Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back…
- Conditions
- Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor
- Trial name
- NCT04322318
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Scan
- Where
- 205 sites in United States, Australia and 4 more
- Volunteers
- 256 people
- Sponsor
- Children's Oncology Group
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of improvement…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma
- Trial name
- NCT05353439
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 15 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
- Trial name
- NCT04106219
- Testing
- LY3295668 Erbumine, Topotecan, Cyclophosphamide
- Where
- 17 sites in United States, Australia and 7 more
- Volunteers
- 71 people
- Sponsor
- Eli Lilly and Company
Platinum-resistant Ovarian Cancer
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are…
- Trial name
- RAINFOL-02 (NCT06619236)
- Testing
- Rina-S, Paclitaxel, Topotecan
- Where
- 177 sites in United States, Australia and 16 more
- Volunteers
- 584 people
- Sponsor
- Genmab
Ovarian Carcinosarcoma, Endometrial Carcinosarcoma
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e.
- Trial name
- ROCSAN (NCT03651206)
- Testing
- Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs
- Where
- 36 sites in France, Italy and 1 more
- Volunteers
- 138 people
- Sponsor
- ARCAGY/ GINECO GROUP
Small-cell Lung Cancer
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
- Trial name
- DLLEVATE (NCT07218146)
- Testing
- ZL-1310, Investigator's Choice of Therapy
- Where
- 165 sites in United States, Austria and 13 more
- Volunteers
- 480 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma.
- Conditions
- Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
- Trial name
- NCT03126916
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- 164 sites in United States, Canada and 1 more
- Volunteers
- 750 people
- Sponsor
- Children's Oncology Group
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resistant recurrent epithelial ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT06994195
- Testing
- BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Ovarian Neoplasms
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer compared to standard treatments.
- Trial name
- NCT07286266
- Testing
- Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
- Where
- 22 sites in Australia, Canada and 3 more
- Volunteers
- 450 people
- Sponsor
- GlaxoSmithKline
Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with…
- Conditions
- Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
- Trial name
- NCT07371663
- Testing
- TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg
- Where
- 3 sites in China
- Volunteers
- 266 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd